Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian CancerBusiness Wire • 05/24/24
Verastem shares surge more than 50% after pancreatic-cancer treatment study dataMarket Watch • 05/23/24
Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic CancerBusiness Wire • 05/23/24
Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business UpdatesBusiness Wire • 05/09/24
Verastem Oncology to Present at the RBC Capital Markets Global Healthcare ConferenceBusiness Wire • 05/07/24
Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical OfficerBusiness Wire • 04/18/24
Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian CancerBusiness Wire • 03/18/24
Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business UpdatesBusiness Wire • 03/14/24
Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women's Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet NeedsBusiness Wire • 03/11/24
Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian CancerBusiness Wire • 03/05/24
Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024Business Wire • 03/05/24
3 Stocks That AI Predicts Will Deliver Triple-Digit Returns This Year: February 2024InvestorPlace • 02/07/24
Verastem: Other Catalysts In 2024 Beyond NDA Rolling Submission Of DefactinibSeeking Alpha • 02/07/24
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven CancersBusiness Wire • 01/29/24
Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)Business Wire • 01/18/24
PRISM MarketView Announces the Addition of Verastem to Emerging Women's Health IndexMCAP MediaWire • 01/12/24
Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology ConferenceBusiness Wire • 01/11/24
Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet TherapeuticsBusiness Wire • 12/18/23
Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian CancerBusiness Wire • 12/13/23